Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
7
×
san francisco blog main
san francisco top stories
7
×
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
deals
drugs
fda
national
san francisco
startups
amgen
cancer
crispr
eli lilly
gene therapy
indiana blog main
indiana top stories
ipo
jefferies
What
big
7
×
week
bio
cas
ceo
companies
crispr
drug
make
medicine
medicines
meeting
new
startup
today
year
aces
admits
ago
aiming
ambys
american
announced
approval
arguments
ash
available
based
biosciences
biotech
biotechs
blood
bosley's
bosley’s
bridge
bucks
cheaper
cholesterol
class
classes
Language
unset
Current search:
big
×
" national top stories "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?